Tuesday, April 28, 2026, 12:00 PM–1:00 PM ET
Discover how next-day comprehensive genomic profiling (CGP) is possible with the Oncomine Comprehensive Assay Plus on the Genexus System—delivering both speed and accuracy.
Webinar presenters Jane Bayani, MHSc, PhD, Assistant Professor and Co-Director, Diagnostic Development, Ontario Institute for Cancer Research, Canada, and Nicola Normanno, MD, Scientific Director, IRCCS Romagnolo Institute for the Study of Tumors, Italy, and Morten Grauslund, PhD, Molecular Biologist, Department of Pathology, Rigshospitalet/Copenhagen University Hospital, Copenhagen, Denmark.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Thermo Fisher Scientific. For Research Use Only. Not for use in diagnostic applications.
Thursday, April 30, 2026, 11:00 AM–12:00 PM ET
Hear an expert discuss how Memorial Sloan Kettering Cancer Center (MSKCC) is utilizing
the oncoReveal® Nexus 21-gene panel to redefine turnaround time and actionable insights
in cancer care. Dr. Ewalt shares a perceptive look at the clinical need for rapid, front-line NGS sequencing, and how a unique, purpose built targeted NGS panel (Pillar Biosciences’ oncoReveal Nexus 21 gene Panel) was developed, validated and implemented clinically by Memorial Sloan Kettering Cancer Center (MSK-REACT) to complement their current comprehensive genomic profiling (CGP) approach.
Webinar presenter Mark Ewalt, MD, Associate Medical Director for Laboratory Operations for Diagnostic Molecular Pathology in the Molecular Diagnostics Service, Department of Pathology and Laboratory Medicine, MSKCC.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Pillar Biosciences.
Thursday, May 28, 2026, 1:00–2:00 PM ET
This session is designed to improve understanding and application of recent updates to synoptic pathology reporting protocols such as the latest Reporting Template for Reporting Results of Biomarker Testing of Specimens from Patients with Carcinoma of the Breast. These changes reflect evolving clinical guidelines that directly influence diagnostic accuracy and treatment selection in breast cancer care.
Webinar presenters Thaer Khoury, MD, FCAP, Chair, Pathology and Laboratory Medicine, Roswell Park Comprehensive Cancer Cente, and Colin Murphy, CEO of mTuitive.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
January 2017—Becton Dickinson launched its next generation wireless rapid diagnostic system for detection of influenza A and B, respiratory syncytial virus, and group A strep, with new traceability and secure patient health record documentation features and functionality.
January 2017—EntroGen launched its Leukemia Translocation Panel, a multiplexed, one-step RT-PCR assay that detects 10 variants in six common leukemia-associated translocations simultaneously from total RNA isolated from blood or bone marrow. The assay is compatible with several leading multichannel real-time PCR instruments capable of detecting four commonly used fluorescent probes and produces results in 90 minutes.
November 2016—Siemens Healthineers received FDA 510(k) clearance for its Xprecia Stride Coagulation Analyzer, a handheld, portable coagulation analyzer designed to deliver fast, reliable prothrombin time international normalized ratio testing for point-of-care monitoring and management of oral anticoagulation therapy with warfarin.
November 2016—Alere announced it has achieved in vitro diagnostic CE marking in Europe for its Alere Reader, a diagnostic analyzer that can be used in point-of-care and laboratory settings. The Alere Reader will be available initially for use with the Alere BinNow Legionella and Streptococcus pneumonia antigen cards, with other lateral flow applications and assays to follow.
November 2016—Cancer diagnostics and digital pathology workflow solution provider Inspirata has acquired the assets of Boston-based Precision Medicine Network. The acquisition includes Crosswalk Insight: Oncology, a precision medicine decision-support platform.
November 2016—Thermo Fisher Scientific launched the Applied Biosystems TaqPath ProAmp PCR Master Mix. The mixes are developed for high-throughput genotyping and copy number variation protocols requiring accurate results from samples containing PCR inhibitors and are designed to deliver sensitive and reproducible results from genomic DNA targets.
November 2016—Olympus announced that the American Urological Association, together with the Society of Urologic Oncology, included the Olympus Narrow Band Imaging (NBI) technology in its newly released guideline for the diagnosis and treatment of non-muscle invasive bladder cancer.
November 2016—Qiagen launched its Paxgene Blood ccfDNA Tube for venous whole blood collection and room temperature stabilization of in vivo circulating cell-free DNA profiles.
November 2016—Horizon Discovery has entered into a co-development and commercialization agreement with Ventana Medical Systems, a member of the Roche group. The agreement covers the development, manufacture, and commercialization of cell-line derivative materials for use as immunohistochemistry reference standards in cancer tissue diagnostics to support the development and validation of IHC assays.
November 2016—MilliporeSigma introduced its Certified Spiking Solution of intact, heavy labeled thyroglobulin in SigMatrix, a synthetic surrogate serum.
